XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Industry Segment Information
 9 Months Ended
Oct. 03, 2021
Segment Reporting [Abstract]  
Industry Segment Information Segment Information
The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2020 Form 10-K.

The principal products and services of the Company's two operating segments are:
•Discovery & Analytical Solutions. Provides products and services targeted towards the life sciences and applied markets.
•Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market.
The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: 
 Three Months EndedNine Months Ended
 October 3,
2021		October 4,
2020		October 3,
2021		October 4,
2020
 (In thousands)
Discovery & Analytical Solutions
Product revenue$318,456 $245,556 $903,796 $686,529 
Service revenue194,423 178,067 576,521 526,491 
Total revenue512,879 423,623 1,480,317 1,213,020 
Operating income from continuing operations7,146 42,689 114,248 110,632 
Diagnostics
Product revenue467,413 491,290 1,461,384 1,077,352 
Service revenue186,392 49,112 761,143 137,767 
Total revenue653,805 540,402 2,222,527 1,215,119 
Operating income from continuing operations237,903 223,819 965,650 413,710 
Corporate
Operating loss from continuing operations(23,079)(18,502)(57,664)(56,015)
Continuing Operations
Product revenue785,869 736,846 2,365,180 1,763,881 
Service revenue380,815 227,179 1,337,664 664,258 
Total revenue1,166,684 964,025 3,702,844 2,428,139 
Operating income from continuing operations221,970 248,006 1,022,234 468,327 
Interest and other expense, net (see Note 5)60,302 14,249 54,027 35,054 
Income from continuing operations before income taxes$161,668 $233,757 $968,207 $433,273